A recent blog post by the Sidney Kimmel Cancer Center – Jefferson Health examined whether the power of immunotherapy can be used to treat pancreatic cancer. The blog featured a discussion between Jonathan Brody, PhD, director of the Research Division and Professor of Surgery at Thomas Jefferson University and George Prendergast, PhD, chief executive officer of the Lankenau Institute for Medical Research of Main Line Health.
Both Drs. Brody (Gastrointestinal Cancer Program) and Prendergast (co-leader of Cancer Cell Biology Signaling Program) are full members of the NCI-designated Sidney Kimmel Cancer Center at Jefferson, which provided pilot funding support for their initial studies. They are also closely affiliated with the American Association for Cancer Research (AACR); Brody is the 2015 recipient of the Pancreatic Cancer Action Network – AACR Research Acceleration Network Grant, and Prendergast recently finished a term as editor-in-chief of the AACR journal Cancer Research.
Thanks to our colleagues at Jefferson for sharing the blog.
You may also like: